Diabetes and diabetic complications

Sanofi/ TargetBCD

In August 2015, Evotec and Sanofi entered into a strategic collaboration in the field of diabetes. The goal of this collaboration is to develop a beta cell replacement therapy based on functional human beta cells derived from human stem cells. In addition, Sanofi and Evotec will also use human beta cells for high-throughput drug screening to identify beta cell active small molecules or biologics.
Both companies will make significant contributions to this collaboration in terms of expertise, platforms and resources. The collaboration further enhances and complements Sanofi's extensive diabetes portfolio and extends Evotec's metabolic disease and stem cell-based drug discovery programmes.
The agreement between Evotec and Sanofi triggers an upfront payment of EUR 3 m, potential pre-clinical, clinical, regulatory and commercial milestones which could total over EUR 300 m as well as significant royalties and research payments. 

In April 2017, Evotec has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept.

In June 2018, Evotec has reached its second beta cell therapy milestone, resulting in a payment of € 3 million to Evotec. This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models.

Bayer/ CureNephron

In September 2016, Evotec announced that Evotec and Bayer have entered into a five-year, multi-target research partnership. The goal is the development of multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during pre-clinical development of potential clinical candidates.

Under the terms of the agreement, Bayer received exclusive access to selected candidates as well as to Evotec’s CureNephron target pipeline. Bayer will be responsible for any subsequent clinical development and commercialisation. Evotec will receive a minimum of € 14 m over the contract period including research payments and an undisclosed licence fee. In addition, Evotec is eligible to receive pre-clinical, clinical and sales milestones of potentially over € 300 m as well as tiered royalties of up to low double-digit percentage of net sales. 

AstraZeneca/ Kidney disease

In October 2013, Evotec entered into an agreement with AstraZeneca in the field of kidney diseases. Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease.
Under the terms of this licence and collaboration agreement, AstraZeneca received access to a selected series of molecules identified in a screening effort, which is part of Evotec's systematic kidney disease initiative. This particular programme has been designed to explore a key mechanism in the field of chronic kidney disease. AstraZeneca provides industrial scope and scale as well as pharmaceutical development expertise and marketing capabilities.
The agreement between Evotec and AstraZeneca triggered an undisclosed upfront payment as well as pre-clinical, clinical and regulatory milestones. Evotec is also eligible for additional milestone and royalty payments related to commercialisation. Evotec receives research funding for work that will be conducted in collaboration with AstraZeneca. Specific financial details were not disclosed.

TOP